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Cost of disorders of the brain in Switzerland: with a focus on
mental disorders
Abstract
QUESTIONS UNDER STUDY: This study aims at estimating the costs of disorders of the brain in
Switzerland based on the published epidemiological and economic evidence. Methods: the data
presented for Switzerland are derived from the "cost of disorders of the brain in Europe" study of the
European Brain Counsil (EBC). Available Swiss data were integrated. RESULTS: There are an
estimated 2 million people currently living with a brain disorder in Switzerland. This number amounts to
about 25% of all people living in Switzerland. The total annual costs are estimated to amount to 8.9
billion Euros corresponding to 1200 Euros per inhabitant and per year. Direct medical expenditure
accounts for 33% of all expenditure, while indirect costs add up to 49%. Mental disorders account for
approximately 2/3 of the total costs of brain disorders, ie, 5.6 billion Euros. This cost estimate comes
very close to the current expenses for mental health in Switzerland with 5.3 billion Euros constituting
16% of total health care costs. : The present study probably underestimates the full economic burden of
brain and especially mental disorders in Switzerland. In order to better understand the impact of brain
disorders on Swiss society prospective field studies are needed in all disorders of the brain.
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Questions under study: this study aims at esti-
mating the costs of disorders of the brain in
Switzerland based on the published epidemiolog-
ical and economic evidence. 
Methods: the data presented for Switzerland
are derived from the “cost of disorders of the
brain in Europe” study of the European Brain
Counsil (EBC). Available Swiss data were inte-
grated.
Results: there are an estimated 2 million peo-
ple currently living with a brain disorder in
Switzerland. This number amounts to about 25%
of all people living in Switzerland. The total an-
nual costs are estimated to amount to 8.9 billion
Euros corresponding to 1200 Euros per inhabi-
tant and per year. Direct medical expenditure ac-
counts for 33% of all expenditure, while indirect
costs add up to 49%. Mental disorders account
for approximately 2/3 of the total costs of brain
disorders, ie, 5.6 billion Euros. This cost estimate
comes very close to the current expenses for men-
tal health in Switzerland with 5.3 billion Euros
constituting 16% of total health care costs.
Conclusions: the present study probably under-
estimates the full economic burden of brain and
especially mental disorders in Switzerland. In
order to better understand the impact of brain
disorders on Swiss society prospective field stud-
ies are needed in all disorders of the brain. 
Key words: brain disorder; mental disorder; cost;
cost of illness; economic burden; Switzerland
Summary
In a study based on WHO data, brain disor-
ders as a whole were estimated to account for
35% of the total burden of disease in Europe [2].
Neuropsychiatric diseases have been estimated to
account for 27% of disability adjusted life years
(DALYs) in European countries and have thus
more impact on the global burden of disease than
cardiovascular diseases (17%) or neoplasms
(17%) [41]. While specialisation in many medical
disciplines progresses, a number of similarities
and shared interests between psychiatry and neu-
rology have developed over the last decades. Most
importantly, basic brain research (neuroscience) is
equally relevant to neurology and psychiatry. In
addition brain disorders are preferably viewed to-
gether because politicians and other decision
makers prefer to deal with broader fields of activ-
ity. 
The European Brain Council (EBC) is an ex-
ample of this development to keep brain disorders
together for certain analyses. It is a co-ordinating
council formed by European organisation in psy-
chiatry, neurology, neurosurgery, basic neuro-
science, as well as European patient organisations
in psychiatry and neurology. The brain-related
pharmaceutical industry is also represented. 
Without knowing the size of a problem and
its economic impact, it is difficult to make clear
recommendations about initiatives in research,
teaching and public awareness. Thus, the EBC
has, as its first major task, analysed the burden and
cost of brain disorders in Europe. The major ob-
jective of the “Cost of Disorders of the Brain in
Europe” study has been to present best possible
estimates of the cost of disorders of the brain in
Europe based on the existing literature. The main
results were published in June 2005 [1]. The aim
of the present study is to provide data in particu-
lar for Switzerland and to discuss these data in the
light of the national literature focussing on men-
tal disorders.
Introduction
No financial 
support.
1 On behalf of the
“Cost of Disorders
of the Brain in
 Europe” Study
Group. For names
see [1].
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The methodology of the European study that forms
the basis of the current publication has been described in
detail previously [1]. In brief, twelve different disorders
(or groups of disorders) of the brain were selected be-
cause they were believed to be associated with the highest
cost and because a preliminary survey indicated that at
least some relevant data were available for these disor-
ders. Other disorders that might have been equally costly
or relevant were left out because they were too heteroge-
neous and/or the data basis was too small. The disorders
selected were: addiction, affective disorders, anxiety dis-
orders, brain tumours, dementia, epilepsy, migraine and
other headaches, multiple sclerosis, Parkinson’s disease,
psychotic disorders, stroke and trauma. A steering com-
mittee comprising Jes Olesen, Hans Ulrich Wittchen,
Bengt Jönsson and Patrick Andl in-Sobocki appointed
several groups of experts for each of these disorders.
These persons were considered to be the leading Euro-
pean experts in the epidemiology of the respective disor-
der. In parallel, the steering committee selected a health
economic panel to govern the health economic studies,
which were performed by the Stockholm Health Eco-
nomics Institute under contract with the EBC. The epi-
demiological data used were based on a systematic review
of published epidemiological evidence in Europe. These
reviews have been published separately [3–10, 40].
The main source used for the reviews were elec-
tronic databases (Medline and Web of Science) comple-
mented by national registries and the Internet. 12
months prevalence data were collected in all disorders by
country and stratified according to age, gender and disor-
der severity where published evidence allowed it. In cases
where no national data were available, best possible esti-
mates or extrapolated data were used. 
In parallel, the economists collected all publications
from Europe in English using Medline and HEED
(Health Economic Evaluation Database). These data are
presented in reviews published separately [11–22]. It was
attempted to present all relevant costs including direct
medical costs, direct non-medical costs and indirect costs.
Direct costs include all costs for goods and services used
in prevention, diagnosis, treatment, and rehabilitation,
eg, costs for medical visits, hospitalisation and drugs.
 Direct non-medical costs comprise all other resources
used related to a disease, eg, transportation, social serv-
ices, sheltered accommodation. Indirect costs are grossly
defined as the value of output that is lost due to absence
from work, early retirement and reduced productivity of
the affected persons and their caregivers. So-called intan-
gible costs such as suffering, loss of quality of life etc.
have not been calculated. All economic data were trans-
formed to Euros (€’s) for 2004. 
The epidemiological and health economic data were
then entered into a health economic model as indicated
in figure 1. The data presented in this paper are the
 aggregated results for Switzerland which are imputed
from data observed in other European countries. 
Material and methods
Cost per year of 
disorder/country
Cost per year of brain 
disorders/country
Cost per year of brain 
disorders in Europe
Aggregation on 
diseases
Aggregation on 
countries
MODEL • Adjustment of economic data to 
common timeframe and currency
• Imputation of economic cost data for 
countries where no published evidence 
is available
• Combine economic data with 
epidemiology data
• P (cost per patient) x Q (number of 
patients)
• Add-up costs per brain disorder for 
Europe
• Stratification of results
Figure 1
Health Economic
Model.
Results
Total prevalence
The total number of people with any brain
disorder in Switzerland amounts to 2.0 million in
2004, constituting more than a quarter of all Swiss
inhabitants. This figure is an aggregate of the
prevalence estimation for each brain disorder in-
cluded in the study. However, the prevalence esti-
mates in mental disorders, migraine and epilepsy
are all based on the European patient populations
aged 18–65. The estimates in dementia and
Parkinson’s disease are limited to the population
aged 65 or older, and concerning stroke restricted
to the age group 25 years or older. In this respect
our estimate is conservative. When correcting for
co-morbidity, still one fifth of the Swiss popula-
tion have a brain disorder. 
The number of cases with addiction in
Switzerland amounts to 140’000 (including illicit
drug dependence and alcohol dependence). If we
were to add nicotine dependence to this estimate,
the total number of cases would be approximately
610’000. Affective disorders (depression and bipo-
lar disorder) affect 370’000 persons and anxiety
disorders (panic, phobias, obsessive compulsive
disorder and generalised anxiety disorder)
710’000. 40’000 persons are affected by psychotic
disorders. The most prevalent neurological disor-
der was migraine, with an estimated 630’000
cases. The distribution of estimated cases with
brain disorders in Switzerland across specific dis-
orders are presented in figure 2. Among the less
prevalent brain disorders multiple sclerosis and
brain tumour comprise an estimated 8000 and
1700 cases respectively. 
Cost per patient
Based on a review of economic data in Eu-
rope, the costs per case per disorder for 2004 are
calculated for Switzerland. Sporadic economic
studies in Switzerland have not been integrated in
the European data set. From these data, data for
Switzerland have been used. The cost per patient
for each of the 12 brain disorders is shown in fig-
ure 3. Most costly per case are brain tumours and
multiple sclerosis, each with a relatively low
prevalence rate. Anxiety disorders and migraine,
on the contrary, have a low cost per case but are
very prevalent. 
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Figure 4 
Total cost of brain
disorders in Switzer-
land (€PPP million,
2004)
Total cost of brain disorders
The estimated total cost of all the brain disor-
ders included in Switzerland is 8.9 billion Euros.
Affective disorders are the most costly brain dis-
order followed by dementia and addiction.
Among the neurological disorders migraine is the
most costly followed by epilepsy and stroke. Note
that important cost categories are missing for sev-
eral of the disorders. Indirect costs and direct
non-medical costs are, for example not included
for trauma and direct non-medical costs are not
included for anxiety disorders, migraine and affec-
tive disorders. Indirect costs are not included for
psychotic disorders and alcohol dependence. The
cost of stroke is based on incidence because of
lack of prevalence data and thus grossly underesti-
mated.
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Figure 2
Estimated number of
cases of brain disor-
ders in Switzerland
Note: the number of
cases of stroke and
trauma are based on
incidence data owing
to the lack of appro-
priate prevalence
data in the literature.
Results on addiction
omit nicotine de-
pendence.
Figure 3 
Cost per case of spe-
cific brain disorders
in Switzerland 
(€PPP 2004).
Cost of brain disorders per inhabitant
It is of interest to estimate how much brain
disorders cost each individual citizen in Switzer-
land. These data are given in table 1. Taken to-
gether, cost of brain disorders amount to €1200
per year for each citizen of Switzerland. 
Cost of brain disorders distributed 
by resource items
These data are presented in detail in table 
2 and also as a diagram in figure 5. Direct health
care costs amount to €2.9 billion and constitute
33% of the total cost. Direct non-medical costs
account for €1.7 billion, ie, 19%, and indirect
costs €4.4 billion (49%) mainly because of pro-
ductivity loss due to sick leave. As previously
mentioned, important cost categories are missing
for several of the disorders. 
Brain disorders constitute 13% of the total
direct health care cost in Switzerland. Out of total
drug sales in Switzerland, 17% are used for treat-
ment of brain disorders [23]. The total cost of
brain disorders (direct and indirect combined)
constitute 4% of the gross national product of
Switzerland.
Cost of brain disorders distributed 
by medical speciality and disorder
Attributing disorders to one speciality is po-
tentially misleading. Brain tumours and brain
trauma are not only cared for by neurosurgeons
but also by neurologists and other medical disci-
plines. Similarly, stroke, dementia, and most other
disorders are cared for by more than one medical
discipline and not the least by general practition-
ers. However, for certain purposes an attempt to
split up cost into several disciplines might be use-
ful. We assigned the different brain disorders to
different specialties in table 3. Dementia has been
kept separate, because the responsibility is equally
shared between psychiatry and neurology. The
biggest neurosurgical disorder, herniated disc,
was not included in our study. Mental disorders
(excluding dementia) account for 63% (€5.6 bil-
lion) of the total cost of brain disorders in
Switzerland.
Cost of psychiatric disorders – 
direct Swiss data
Direct healthcare costs of mental disorders
The total direct expenditure for healthcare in
Switzerland amounted to €29 billion in 2003 [27].
In Switzerland the primary sources of mental
health financing in descending order are social in-
surance, tax based and out of pocket expenditure
by the patient. There are no budget allocations
for mental health. 
The total costs of psychiatric hospitals in
Switzerland in 2004 were €0.9 billion which are
10.8% of the costs of all hospitals [28]. The cost
of outpatient private psychotherapy was €365
million in 2000 [29]. Out of total drug sales in
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ures for January 2005 [30]. 8 out of 1000 inhabi-
tants of Switzerland received disability benefits
for mental disorder [31]. Direct non-medical costs
in Switzerland also include social services, oppor-
tunities of housing as well as home care for people
with mental disorders. The total costs of home
care in Switzerland amounted to €0.63 billion in
2004 [32]. The proportion of home care due to
mental disorders was estimated at ¼ of the total
costs, thus €158 million [27]. These figures
amount to €2.1 billion for direct non-medical
costs. The costs of supported housing and psychi-
atric rehabilitation and reintegration in work are
not included. 
Indirect costs of mental disorders
The total costs due to distress at workplace in
Switzerland amount to €2.6 billion, thereof med-
ical costs €0.9 billion, non-prescribed medication
€219 million, sick leave and lost productivity €1.5
billion [33]. An international study in 5 European
countries concludes that the indirect health care
cost due to mental disorders amounts to 3 to 4
percent of GDP (gross domestic product). Two-
thirds account for lost productivity, one-third due
to sick leave [34]. In Switzerland the GDP in 2005
was €286 billion [35]. Thus the indirect mental
health costs would amount to €11.5 billion.
Brain disorder Direct healthcare Direct non-medical Indirect costs Total  
All brain disorders 401 228 598 1226  
Affective disorders 91 0 268 359  
Epilepsy 44 147 0 191  
Addiction 54 10 122 186
Anxiety disorders 86 0 64 150
MS 5 0 84 89
Stroke 61 11 0 72
Migraine 8 13 29 51
Trauma 20 12 10 42
Parkinson’s disease 10 17 12 40
Psychotic disorders 11 16 0 27
Dementia 3 1 8 12
Tumour 9 0 0 9
Table 1
Cost per inhabitant 
of specific brain dis-
orders in Switzerland
(€PPP, 2004).
€ million Cost %  
Direct healthcare costs 2922 33%    
Hospitalisation 1716 19%    
Drugs 213 2%    
Outpatient care 958 11%    
Medical devices 35 0%  
Direct non-medical costs 1661 19%    
Social services 1144 13%    
Informal care 366 4%    
Adaptations 125 1%
Transportation 26 0%  
Total indirect costs 4357 49%
Sick leave 3019 34%    
Early retirement 679 8%   
Premature death 660 7%  
Total costs 8941 100%  
Table 2
Distribution of total
cost of brain disor-
ders in Switzerland
by resource use com-
ponents.
Switzerland, 17% were used for the treatment of
brain disorders that is €364 million without the
drugs used in hospitals because they are counted
in the total costs of running the psychiatric hospi-
tals [23]. The amount of these direct health costs
is €1.7 billion amounting to 5.9% of total direct
healthcare expenditure.
Direct non-medical costs of mental disorders
Disability benefits due to mental disorders
amount to €1.3 billion in 2005 based on the fig-
Discussion
Overall, this study shows that brain disorders
are extremely costly and cause a substantial eco-
nomic burden to Swiss society. These disorders
consume 4% of the gross national product and
cost each Swiss citizen an estimated €1200 per
year. The costs of the mental disorders amount to
€722 per inhabitant. The disorders that are tradi-
tionally regarded as mental disorders account for
approximately 2⁄3 of the total costs while disorders
traditionally regarded as neurological/neurosurgi-
cal account for the remaining 1⁄3 of the cost of
brain disorders. Another general trend is that the
highly prevalent disorders such as anxiety and mi-
graine are inexpensive per case but, due to their
high prevalence, are very costly to society. Affec-
tive disorders are the most costly brain disorders
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because they are both rather prevalent and costly
per case. This is also in line with the general cost-
ing picture of brain disorders in Europe. 
Direct prospective studies conducted in
Switzerland would of course have been the best
way of estimating the cost of brain disorders in
Switzerland. However, to our knowledge no com-
prehensive studies have been conducted. The im-
puted data of the present study can be compared
to direct Swiss data obtained from public authori-
ties, social services and national literature regard-
ing costs of several brain disorders. In the follow-
ing we focus on mental disorders. A study by
Schopper, Pereira et al. (2000) found that the pro-
portion of total disease burden expressed in dis-
ability adjusted life years (DALYs) due to mental
disorders (depression, alcohol abuse, suicides, ob-
sessive-compulsive disorder and schizophrenia)
was 21% in the canton of Geneva. Ischaemic heart
disease and cerebrovascular diseases contributed
to DALYs with 11%, neoplasms (respiratory sys-
tem and breast) with 5%, AIDS with 5% [24]. 
Prevalence of mental disorders in Switzerland
The overall one-year prevalence of any men-
tal disorder including addiction is 24% correspon -
ding to 1.75 million inhabitants [25]. This finding
is consistent with a study by Wittchen & Jacobi
that 27% of the adult EU population, 18-65 of
age, is affected by at least one mental disorder in
the preceding 12 months [26]. The imputed data
presented here, demonstrate that 1.25 million
people in 2004 equivalent to 17% of the popula-
tion suffer from addiction, affective, psychotic or
anxiety disorder. These figures suggest an under-
estimation of the prevalence of mental disorders
by the present study and as such an underestima-
tion of costs. One further reason for having un-
derestimated the cost might be that the present
study only counted the four major groups of men-
tal disorders.
Costs of mental disorders in Switzerland
The total direct healthcare costs for psychi-
atric disorders in Switzerland according to direct
Swiss data amount to €1.7 billion. This figure is
close to the present estimate of €2.1 billion. The
estimate based on Swiss data does not include
outpatient treatment other than psychotherapy.
However, the Swiss data includes the costs of all
mental disorders while the estimated data pre-
sented here only comprise psychosis, addiction,
affective and anxiety disorders.
The total direct non-medical costs for psychi-
atric disorders in Switzerland according to direct
Swiss data amount to €2.1 billion. In the present
study direct non-medical costs for mental disor-
ders were estimated to be €157 million. However,
this figure is not comparable with the direct Swiss
data because the latter includes all psychiatric dis-
orders while the present estimate only includes
addiction and psychotic disorders. Furthermore,
the imputed data do not include the cost of dis-
ability benefits. 
According to direct Swiss data the indirect
2%
11%
13%
4%
34%
8%
7%
2%
19%
    Hospitalization
    Drugs
    Outpatient care
    Social services
    Informal care
    Other direct costs
    Sick leave
    Early retirement
    Premature death
Figure 5 
Distribution of total
cost of brain disor-
ders in Switzerland
by resource item
components.
Note. Direct non-
medical costs are
missing for the
 following disorders:
affective disorders,
anxiety disorders,
 migraine and trauma.
Indirect cost is miss-
ing for psychotic 
disorder. Only indi-
rect costs due sick-
leave were included
in anxiety disorders. 
€ million Healthcare Direct non-medical Indirect  Total
costs costs costs cost
Neurosurgical disorders 88 5 57 150
Brain tumour 22 5 57 84
Trauma 67 67
Neurological disorders 391 427 987 1804
Epilepsy 58 98 214 371
Migraine and other headaches 34 613 647
Multiple sclerosis 76 127 84 288
Parkinson’s disease 78 116 193
Stroke 144 85 75 304
Neurological/mental disorder 320 1072 1392
Dementia 320 1072 1392
Mental disorders 2124 157 3314 5595
Addiction 391 74 893 1358
Affective disorders 664 1954 2618
Anxiety disorders 625 467 1091
Psychotic disorders 445 83 527
All brain disorders 2922 1661 4357 8941
Table 3
Cost of brain disor-
ders in Switzerland
by disorder area
(€PPP million).
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mental health costs due to sick leave and lost pro-
ductivity in Switzerland amount to €1.5 billion. In
the present study the indirect costs were domi-
nant cost components, particularly in mental dis-
orders. These are primarily due to reduced pro-
ductivity and premature retirement caused by
both morbidity and mortality. In the present
study indirect costs for mental disorders were es-
timated at €3.3 billion without psychotic disor-
ders. As the above-mentioned figures show a
great variability in composition it is difficult to
compare these figures. 
However, the total costs of mental disorders
based on direct Swiss data amount to €5.3 billion
which is close to the estimates of the present
study that indicates that mental disorders cost
€5.6 billion per year.
Restrictions of the present cost estimates
There are many reasons why the present cost
estimates are extremely conservative. Firstly,
many important brain disorders have not been in-
cluded in this study because data are lacking.
Thus, mental retardation, developmental disor-
ders, eating disorders and neuromuscular disor-
ders are not included. We also have not included
tobacco addiction, which would add a significant
amount to the cost of addiction. Many cost cate-
gories are missing, for example indirect costs for
psychotic disorders and alcohol dependence and
direct non-medical costs of affective and anxiety
disorders. One of the main difficulties encoun-
tered in the present study was a lack of good stud-
ies in Switzerland and Europe, making extrapola-
tions relatively uncertain. Furthermore, studies
were done at different times, using different
methodology, focusing on different segments of
the population and using different health eco-
nomic categories or principles. For all these rea-
sons, they have been difficult to put together. Fur-
thermore the cost categories of the direct Swiss
data were not consistently equivalent with the
categories of the present estimation contributing
to the difficulty in comparing the cost data of
both sources.
The external validation of the results of the
present study applied to the European population
as a whole, shows that it is in relatively strong
concordance with previous research findings in
the literature [1]. The comparison indicates possi-
ble underestimation in mental disorders, first and
foremost due to missing data. Further critical
methodological issues have been described and
discussed previously [1]. 
Nevertheless the present study presents the
best possible estimate of the cost of brain disor-
ders, especially mental disorders in Switzerland.
Cost data are, however, extremely important for
decision makers. It makes sense that costly disor-
ders should receive more attention than less
costly disorders. Furthermore, exact cost data are
important to analyse effects of interventions and
to calculate whether increased research effort or
increased clinical effort would pay off. The pres-
ent study strongly indicates the need for further
research in brain disorders both in terms of epi-
demiology and health economics at European and
at national level. 
Comparison with cost and burden 
of other disorders
We are not aware of other Swiss studies sum-
marising the epidemiology, burden and cost of
other major groups of disorders such as heart dis-
orders, cancer or diabetes. Even at the European
level and in the USA such data are scarce. Data on
diabetes, cancer and heart disorders from foreign
sources indicate that brain disorders constitute the
most costly group. This is in accordance with the
burden of disorders of the brain study showing
that, in Europe, brain disorders are responsible for
35% of the total burden of all disorders [2].
In Switzerland few studies concerning the
burden of different groups of disorders have been
conducted. One study estimated the total annual
costs caused by overweight and obesity to €1.7
billion [36]. The burden of illness of severe sepsis
was estimated to range from €0.3 to 0.8 billion
per year [37]. Asthma is considered to be a major
healthcare cost factor in Switzerland, amounting
to approximately € 0.8 billion per year [38]. 
Corresponding to the WHO data on the bur-
den of disease in Europe, the costs of brain disor-
ders are bigger than the costs of cancer and dia-
betes combined [2]. It also has been shown that
the burden of brain diseases and therefore also
the costs of brain disorders will increase markedly
during the next two decades due to the ageing
population in Europe. In the 5th framework pro-
gramme of the EU (FWP, 1998–2002) only 8% of
research funding was allocated to brain research.
Clearly, there is a need for an increase in this rela-
tively small amount considering the huge cost and
burden of brain disorders. 
However, it should be remembered that
health care expenditure must not necessarily
equal the burden of disorder. It must also reflect
available treatment possibilities. The problem of
whether or not sufficient resources are allocated
to the care of brain disorders cannot be solved
using the present data, but needs a much more
penetrating analysis. 
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In Switzerland with a population of 7.3 mil-
lion, an estimated 2 million inhabitants currently
suffer from one or more brain disorders. Brain
disorders figure amongst the leading causes of
death and disability. Yet, the knowledge of the epi-
demiological and economic impact of brain disor-
ders has been relatively little researched in
Switzerland. The present study estimated the total
cost of brain disorders in Switzerland to €8.9 bil-
lion in 2004, which corresponds to a cost of €1200
per capita. Direct medical expenditure alone to-
talled €2.9 billon, comprising hospitalisation (€1.7
billion), outpatient care (€1.0 billion) and drug
costs (€0.2 billion). Attributable indirect costs re-
sulting from lost workdays and productivity loss
due to permanent disability and mortality
amounted €4.4 billion. Direct non-medical costs
(social services, informal care and others) totalled
€1.7 billion in 2004. These estimates include the
most prevalent brain disorders. Due to scarcity of
data the results only partially include direct non-
medical cost and indirect costs and omit intangi-
ble costs completely. 
This study has exclusively evaluated the pub-
lished evidence. As such data were largely missing
in Switzerland the total costs of the several brain
disorders were estimated through a model based
on available data in other countries. 
The present estimates for mental disorders
were compared with available data in Switzerland.
The present imputed data estimated the total
costs of mental disorders at €5.6 billion thereof
direct healthcare costs €2.1 billion, direct non-
medical costs €0.2 billion and indirect costs €3.3
billion. The review of direct Swiss data resulted in
the following cost estimations. Direct health care
costs amounted to €1.7 billion, direct non-med-
ical costs were estimated at €2.1 billion including
disability benefits, indirect costs at €1.5 billion.
These figures amount to €5.3 billion which is very
close to the present estimates of the extrapolated
data. With respect to the many restrictions of the
cost estimates both the imputed data as well as di-
rect Swiss data, the total costs of mental disorders
in Switzerland seem to amount to €5.3 to 5.6 bil-
lion corresponding to 16 to 17% of the total costs
of the health system in Switzerland (€32.5 billion,
[39]).
The present study probably underestimates
the full economic burden of brain disorder in
Switzerland because of major shortcomings in the
epidemiologic and economic knowledge of brain
disorders in Switzerland. Furthermore, treatment
patterns and care provided to patients change over
time. In order to better understand the impact of
brain disorders to Swiss society prospective field
studies are needed in all disorders of the brain.
Theses efforts need to be done in close collabora-
tion between epidemiological experts and health
economic experts in the field.
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